source
- Eli Lilly to buy psychedelics biotech AtaiBeckley for $2.8 billionEli Lilly announced it will acquire AtaiBeckley, a biotech focused on psychedelic therapies for mental health, for an upfront cash payment of $2.8 billion. The purchase adds a new dimension to Lil…
- UnitedHealth beats Q2 forecasts but warns rising insurance costs will strain employersUnitedHealth Group reported second-quarter results that exceeded analysts' expectations, lifting its shares modestly. Despite the upbeat earnings, executives highlighted that medical expenses for…